Quantcast

Latest Breast cancer classification Stories

2014-06-04 15:29:19

Albert Einstein College of Medicine The study was led by researchers at the National Cancer Institute (NCI)─designated Albert Einstein Cancer Center of Albert Einstein College of Medicine of Yeshiva University and Montefiore Einstein Center for Cancer Care and was published online today in the Journal of the National Cancer Institute (JNCI). "Tests assessing metastatic risk can help doctors identify which patients should receive aggressive therapy and which patients should be spared,"...

2014-05-14 20:23:48

CLEVELAND, May 14, 2014 /PRNewswire/ -- Researchers from University Hospitals (UH) Case Medical Center's Seidman Cancer Center will present findings from a study that found the presence of tumor-infiltrating lymphocytes, a type of white blood cell, ahead of treatment may help predict response to platinum-based chemotherapy in women with triple-negative breast cancer. The data are being presented at the 50(th) American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago....

2014-04-11 11:57:29

Most breast cancers are treated by blocking their addictions, for example depriving estrogen-fueled tumors of estrogen. But what about breast cancers without these hormonal addictions? In so-called "triple negative" tumors the cancer's addiction remains a mystery, making this subtype difficult to treat. However, a University of Colorado Cancer Center study presented today at the American Association for Cancer Research (AACR) Annual Meeting 2014 showcased a new drug active against...

2014-01-15 08:28:21

Trial Will Compare Investigational Compound's Efficacy and Safety as an Addition to Standard Treatment NORTH CHICAGO, Ill., Jan. 15, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the initiation of a Phase 3 clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888) when added to carboplatin, a chemotherapy, in women with early-stage, triple-negative breast cancer. The three-arm trial will compare the addition of veliparib plus...

2014-01-07 08:30:40

- Agreement to Distribute Oncotype DX(R) in Australia and New Zealand MELBOURNE, Australia, Jan. 7, 2014 /PRNewswire/ -- Australian women will potentially have greater access to the only genomic test validated to predict whether patients with early-stage invasive breast cancer would benefit from chemotherapy, following an agreement between Specialised Therapeutics Australia (STA) and Genomic Health, Inc. (NASDAQ: GHDX). STA has struck an agreement to represent the important...

2013-12-12 10:49:59

Genetic signature identifies patients with more aggressive triple-negative cancers A new test has the potential to help physicians identify patients with the most lethal forms of triple-negative breast cancer, a disease which requires aggressive and innovative treatment. The test, described in the Dec. 11 issue of PLOS ONE, was able to distinguish between patients with a good or poor prognosis, even within groups of patients already stratified by existing tests such as MammaPrint and...

2013-12-03 11:13:26

Researchers from the University of Alberta and Alberta Health Services have created a computer algorithm that successfully predicts whether estrogen is sending signals to cancer cells to grow into tumors in the breast. By finding this hormone receptor, known as estrogen receptor positive, physicians can prescribe anti-estrogen drug therapies, improving patient outcomes. Since each cell in the body contains 23,000 genes, identifying the specific genes involved in cancer growth is an...

New Compound BH3 Mimetics Future Of Breast Cancer Treatment
2013-07-09 09:40:18

[ Watch the Video: New Anti-Cancer Compound Shows Promise For Breast Cancer ] Rebekah Eliason for redOrbit.com - Your Universe Online Scientists from Melbourne, Australia recently discovered compounds currently being researched to treat leukemia may also be effective in treating the most common form of breast cancer. Researchers found a group of anti-cancer compounds known as BH3-mimetics are effective for treating estrogen receptor-positive (ER-positive) forms of breast cancers when...

2013-06-03 12:32:40

The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes 's expression – among them mutations, amplifications, substitutions, and translocations – have been found in 14 different advanced solid tumors. The results of the study of more than 2,000 tumors, being presented at the annual meeting of the American Society of Clinical Oncology (ASCO), both surprised researchers and provided hope that some of...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related